:format(jpeg):focal(1545x410:1555x400)/cloudfront-us-east-1.images.arcpublishing.com/gfrmedia/ITRVWLHMTRB3TCOSYZ2AGT5SSE.jpg)
The Food and Drug Administration (FDA in English) presented a proposal to begin regulating clinical laboratory analyzesa multimillion-dollar business that it claims causes increasing risk to patients due to potentially erroneous results.
The proposed rule will end decades of regulatory ambiguity and formally place the thousands of tests performed in large laboratories under FDA oversight. Commissioner Robert Califf said the change will help Ensure that tests used to diagnose cancer, heart failure and thousands of other diseases are safe, accurate and reliable.
“A growing number of clinical diagnostic tests created by laboratories are offered without guarantees of their effectiveness,” Califf said in a statement. He added that he is concerned about the agency that many tests offered by laboratories are not as accurate or reliable as those subject to the FDA for review.
Here’s a look at the history and context of the analytics problem.
What are clinical laboratory tests?
Most people are familiar with clinical tests such as those used to diagnose COVID-19, strep throat, and other health disorders. The tests are made by a handful of large labs and are subject to FDA oversight before they are sold to hospitals, doctors’ offices or pharmacies.
The tests targeted by the recent FDA action are created and used by high-tech laboratories, such as those applied at academic medical centers and companies such as Quest Diagnostics. They include tests to diagnose complex diseases such as cancer or simpler disorders such as high cholesterol and sexually transmitted infectious diseases.
In the 1970s and 1980s, most lab tests were “low-risk, small-volume” products used primarily for local patients, the FDA said Friday.
Over time, the analyzes created by laboratories have become a multimillion-dollar business in which thousands of blood, urine and other fluid or tissue samples sent by hospitals and clinics are processed weekly. Others target their advertising directly to consumers; Some even aim to measure the risk of contracting Alzheimer’s or autism.
Laboratory tests have avoided FDA oversight even though the agency has always said it has the authority to intervene. Debate over regulation of the industry dates back to the 1990s, and several government advisory bodies have recommended greater oversight by the FDA.
Why does the FDA want to regulate now?
Many laboratory tests are central elements of medical care and They are used to make important decisions about pregnancy, nutrition, or many other health matters.
FDA officials have long raised concerns about the accuracy of some tests, since There are known cases of patients receiving erroneous results for heart failure, Lyme disease, cancer, and other disorders. Incorrect results can lead to incorrect diagnoses, lack of treatment, or prescribing unnecessary medications or surgeries.
More than 10 years ago, the agency developed stricter standards for the sector, but never made them concrete.
The analyzes attracted greater scrutiny after the fall of the founder and CEO of the Theranos laboratory, Elizabeth Holmes, sentenced to prison last year for misleading investors about the prospects of his company’s blood tests.
During the pandemic, the FDA warned about the inaccuracy of dozens of COVID-19 tests that labs in the United States rushed to market without oversight.
Recently, surveillance has begun on pregnancy tests that aim to detect mutations capable of causing Down syndrome, cystic fibrosis and genetic defects. Several studies have identified tests that misdiagnose or exaggerate the risks of these disorders.
What do the analysis manufacturers think?
The laboratories maintain that the FDA regulation will stifle their ability to innovate and quickly develop new tests. They also claim that the new rules are unnecessary because they will duplicate existing ones.
Under a quirk of federal law, Clinical analysis laboratories are supervised by the same agency that runs Medicare and Medicaid, government health insurance for the elderly, disabled or poor. The inspectors evaluate the conditions and procedures of the laboratories, but not the specific analyzes or the advertising that promotes them in the market.
Last year, lawmakers drafted a bill – backed by FDA officials – that would have authorized the agency to regulate high-risk tests. But the sector’s lobbyists managed to get it defeated in the chambers.
What is the FDA proposing?
Under the new proposal, the FDA will gradually adopt stricter standards for regulating laboratories over five years. Some tests already on the market will be exempt, but the FDA wants to hear from the public. At the end of the process, most new analyzes will be subject to FDA standards and regulations.
The new regulations will reduce health care costs caused by “unsafe or ineffective tests, including those promoted with false or misleading advertising,” according to the agency.
The agency will take public comments on its proposal for 60 days before developing a final draft. The process, which has no deadlines, usually takes months or years.
